Plus Therapeutics获AMA PLA编码授权，推动Cnside®脑脊液肿瘤细胞计数检测在美国的商业化与医保覆盖

美股速递04-07

Plus Therapeutics, Inc. 近日宣布，其Cnside®脑脊液肿瘤细胞计数检测已获得美国医学会（AMA）颁发的专属实验室分析（PLA）编码。这一重要进展将显著促进该检测在美国市场的医保报销进程与商业应用推广。

PLA编码的授予为Cnside®检测的广泛临床采用奠定了坚实基础，标志着其在精准肿瘤诊断领域迈出了关键一步。此举预计将优化检测服务的报销流程，加速其融入美国主流医疗体系。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1184710730?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-07 19:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184710730","market":"us","top_or_hot":-1,"title":"Plus Therapeutics获AMA PLA编码授权，推动Cnside®脑脊液肿瘤细胞计数检测在美国的商业化与医保覆盖","media":"美股速递","content":"<p>Plus Therapeutics, Inc. 近日宣布，其Cnside®脑脊液肿瘤细胞计数检测已获得美国医学会（AMA）颁发的专属实验室分析（PLA）编码。这一重要进展将显著促进该检测在美国市场的医保报销进程与商业应用推广。</p>\n<p>PLA编码的授予为Cnside®检测的广泛临床采用奠定了坚实基础，标志着其在精准肿瘤诊断领域迈出了关键一步。此举预计将优化检测服务的报销流程，加速其融入美国主流医疗体系。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Plus Therapeutics获AMA PLA编码授权，推动Cnside®脑脊液肿瘤细胞计数检测在美国的商业化与医保覆盖</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPlus Therapeutics获AMA PLA编码授权，推动Cnside®脑脊液肿瘤细胞计数检测在美国的商业化与医保覆盖\n</h2>\n\n<h4 class=\"meta\">\n\n2026-04-07 19:33 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Plus Therapeutics, Inc. 近日宣布，其Cnside®脑脊液肿瘤细胞计数检测已获得美国医学会（AMA）颁发的专属实验室分析（PLA）编码。这一重要进展将显著促进该检测在美国市场的医保报销进程与商业应用推广。\nPLA编码的授予为Cnside®检测的广泛临床采用奠定了坚实基础，标志着其在精准肿瘤诊断领域迈出了关键一步。此举预计将优化检测服务的报销流程，加速其融入美国主流医疗体系。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PSTV","symbol_name":"Plus Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1184710730","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184710730","pubTimestamp":1775561589,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Plus Therapeutics, Inc. 近日宣布，其Cnside®脑脊液肿瘤细胞计数检测已获得美国医学会（AMA）颁发的专属实验室分析（PLA）编码。这一重要进展将显著促进该检测在美国市场的医保报销进程与商业应用推广。\nPLA编码的授予为Cnside®检测的广泛临床采用奠定了坚实基础，标志着其在精准肿瘤诊断领域迈出了关键一步。此举预计将优化检测服务的报销流程，加速其融入美国主流医疗体系。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"PSTV":"Plus Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Plus Therapeutics Receives AMA PLA Coding Authorization to Drive Cnside ® Commercialization and medical insurance coverage of cerebrospinal fluid tumor cell count detection in the United States","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSTV":1},"content_text":"Plus Therapeutics, Inc. 近日宣布，其Cnside®脑脊液肿瘤细胞计数检测已获得美国医学会（AMA）颁发的专属实验室分析（PLA）编码。这一重要进展将显著促进该检测在美国市场的医保报销进程与商业应用推广。\nPLA编码的授予为Cnside®检测的广泛临床采用奠定了坚实基础，标志着其在精准肿瘤诊断领域迈出了关键一步。此举预计将优化检测服务的报销流程，加速其融入美国主流医疗体系。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184710730","isCrawlerRequest":true}